Novartis' chronic lung disease drug wins approval in EU, Japan

09/25/2013 | PharmaTimes (U.K.)

Novartis obtained approval from the European Commission to market its once-daily Ultibro Breezhaler, or QVA149, as a maintenance therapy for chronic obstructive pulmonary disease. The Japanese Ministry of Health, Labour and Welfare approved Ultibro Inhalation Capsules, delivered using the Breezhaler device, to treat symptoms of COPD.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN